{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:21:51Z","timestamp":1790914911033,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Amgen K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"DOI":"10.1007\/s00774-022-01332-8","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T06:03:52Z","timestamp":1653977032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease"],"prefix":"10.1007","author":[{"given":"Akimitsu","family":"Miyauchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuro","family":"Hamaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cae","family":"Tolman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Shimauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"1332_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12018-016-9211-7","volume":"14","author":"N Yoshimura","year":"2016","unstructured":"Yoshimura N, Nakamura K (2016) Epidemiology of locomotive organ disorders and symptoms: an estimation using the population-based cohorts in japan. Clin Rev Bone Miner Metab 14:68\u201373","journal-title":"Clin Rev Bone Miner Metab"},{"key":"1332_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab016","author":"M Takeuchi","year":"2021","unstructured":"Takeuchi M, Shinkawa K, Yanagita M, Kawakami K (2021) Prevalence, recognition and management of chronic kidney disease in Japan: population-based estimate using a healthcare database with routine health checkup data. Clin Kidney J. https:\/\/doi.org\/10.1093\/ckj\/sfab016","journal-title":"Clin Kidney J"},{"key":"1332_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","volume":"106","author":"A Broadwell","year":"2021","unstructured":"Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S, Kendler D, Messina O, Miller PD (2021) Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106:397\u2013409","journal-title":"J Clin Endocrinol Metab"},{"key":"1332_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","volume":"14","author":"S Klawansky","year":"2003","unstructured":"Klawansky S, Komaroff E, Cavanaugh PF Jr, Mitchell DY, Gordon MJ, Connelly JE, Ross SD (2003) Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 14:570\u2013576","journal-title":"Osteoporos Int"},{"key":"1332_CR5","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00198-018-4592-8","volume":"29","author":"H Chen","year":"2018","unstructured":"Chen H, Lips P, Vervloet MG, van Schoor NM, de Jongh RT (2018) Association of renal function with bone mineral density and fracture risk in the Longitudinal Aging Study Amsterdam. Osteoporos Int 29:2129\u20132138","journal-title":"Osteoporos Int"},{"key":"1332_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2215\/CJN.09130912","volume":"8","author":"MJ Elliott","year":"2013","unstructured":"Elliott MJ, James MT, Quinn RR, Ravani P, Tonelli M, Palacios-Derflingher L, Tan Z, Manns BJ, Kline GA, Ronksley PE, Hemmelgarn BR (2013) Estimated GFR and fracture risk: a population-based study. Clin J Am Soc Nephrol 8:1367\u20131376","journal-title":"Clin J Am Soc Nephrol"},{"key":"1332_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"1332_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19\u201326","journal-title":"J Bone Miner Res"},{"key":"1332_CR9","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"1332_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, Gielen E, Milmont CE, Libanati C, Grauer A (2019) One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res 34:419\u2013428","journal-title":"J Bone Miner Res"},{"key":"1332_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-019-0608-z","volume":"14","author":"A Miyauchi","year":"2019","unstructured":"Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J (2019) Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos 14:59","journal-title":"Arch Osteoporos"},{"key":"1332_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00774-020-01147-5","volume":"39","author":"A Miyauchi","year":"2021","unstructured":"Miyauchi A, Hamaya E, Yang W, Nishi K, Libanati C, Tolman C, Shimauchi J (2021) Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial. J Bone Miner Metab 39:278\u2013288","journal-title":"J Bone Miner Metab"},{"key":"1332_CR13","unstructured":"Amgen, Astellas (2021) Evenity\u00ae subcutaneous injection 105 mg: package insert in Japan (in Japanese). https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/112922_3999449G1025_1_06. Accessed 8 Sept 2021"},{"key":"1332_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2215\/CJN.07670712","volume":"8","author":"S Pelletier","year":"2013","unstructured":"Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8:819\u2013823","journal-title":"Clin J Am Soc Nephrol"},{"key":"1332_CR15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2215\/CJN.01370211","volume":"6","author":"TB Drueke","year":"2011","unstructured":"Drueke TB, Lafage-Proust MH (2011) Sclerostin: just one more player in renal bone disease? Clin J Am Soc Nephrol 6:700\u2013703","journal-title":"Clin J Am Soc Nephrol"},{"key":"1332_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"1332_CR17","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","volume":"53","author":"AS Levey","year":"2007","unstructured":"Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, Collaboration CKDE (2007) Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53:766\u2013772","journal-title":"Clin Chem"},{"key":"1332_CR18","first-page":"1","volume":"2011","author":"Kidney Disease: Improving Global Outcomes, CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes, CKD-MBD Update Work Group (2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2011:1\u201359","journal-title":"Kidney Int Suppl"},{"key":"1332_CR19","first-page":"403","volume":"56","author":"E Imai","year":"2011","unstructured":"Imai E, Yasuda Y, Makino H (2011) Japan Association of Chronic Kidney Disease Initiatives (J-CKDI). Japan Med Assoc J 56:403\u2013405","journal-title":"Japan Med Assoc J"},{"key":"1332_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1001\/archinte.167.2.133","volume":"167","author":"KE Ensrud","year":"2007","unstructured":"Ensrud KE, Lui LY, Taylor BC, Ishani A, Shlipak MG, Stone KL, Cauley JA, Jamal SA, Antoniucci DM, Cummings SR, Osteoporotic Fractures Research Group (2007) Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 167:133\u2013139","journal-title":"Arch Intern Med"},{"key":"1332_CR21","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.2169\/internalmedicine.8618-16","volume":"56","author":"K Nitta","year":"2017","unstructured":"Nitta K, Yajima A, Tsuchiya K (2017) Management of osteoporosis in chronic kidney disease. Intern Med 56:3271\u20133276","journal-title":"Intern Med"},{"key":"1332_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1210\/jc.2013-2786","volume":"99","author":"D Cejka","year":"2014","unstructured":"Cejka D, Marculescu R, Kozakowski N, Plischke M, Reiter T, Gessl A, Haas M (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99:248\u2013255","journal-title":"J Clin Endocrinol Metab"},{"key":"1332_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115223","volume":"133","author":"M Martin","year":"2020","unstructured":"Martin M, Sansalone V, Cooper DML, Forwood MR, Pivonka P (2020) Assessment of romosozumab efficacy in the treatment of postmenopausal osteoporosis: results from a mechanistic PK-PD mechanostat model of bone remodeling. Bone 133:115223","journal-title":"Bone"},{"key":"1332_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/annrheumdis-2020-eular.4539","volume":"79","author":"P Miller","year":"2020","unstructured":"Miller P, Adachi J, Albergaria BH, Cheung AM, Chines A, Gielen E, Langdahl B, Miyauchi A, Oates M, Reid I, Ruiz Santiago N, Vanderkelen M, Yang W, Yu Z (2020) OP0297 efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. Ann Rheum Dis 79:185","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-022-01332-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-022-01332-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-022-01332-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T06:11:27Z","timestamp":1653977487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-022-01332-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":24,"alternative-id":["1332"],"URL":"https:\/\/doi.org\/10.1007\/s00774-022-01332-8","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"4 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Miyauchi received consulting fees from Amgen K.K., and Teijin Pharma. E. Hamaya, K. Nishi, and J. Shimauchi are employees of Amgen K.K., and E. Hamaya owns stock in Amgen Inc. C. Tolman is an employee of Amgen K.K. and owns stock in Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The trial was conducted according to the Declaration of Helsinki: ethical principles for medical research involving human subjects, and the study protocol was approved by the ethics committee or institutional review board at each study center. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}